Shanta Biotechnics is planning to set up a Rs 30 crore plant to manufacture bacterial vaccines.
The plant will focus on manufacturing combination vaccines, and plans to initially manufacture DPT - Hepatitis B combination vaccines.
Addressing a press conference here on Saturday, Shanta's managing director Varaprasad Reddy said that part of the total estimated project cost of Rs 30 crore would be financed through internal accruals, while Exim Bank agreed to provide the rest as term loan.
Reddy also mentioned that the company had bagged long- term contracts worth Rs 80 crore from Iran and Egypt for supply of Hepatitis B vaccine.
